Mepenzolate

Mepenzolate

SCHEMBL3635487

Br.C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1.[Al+3]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM3

The experimentally established mechanism targets of Mepenzolate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 12/20 0.95
CHRM1 known ✓ P11229 4/20 0.74
CHRM2 P08172 11/20 0.95
KCNH2 Q12809 5/20 0.95
CYP2D6 P10635 3/20 0.95
LMNA P02545 2/20 0.95
SLC6A4 P31645 2/20 0.95
CYP2C19 P33261 1/20 0.95
SLC22A1 O15245 1/20 0.93
HRH1 P35367 3/20 0.74
RAB9A P51151 1/20 0.72
CHRM4 P08173 2/20 0.60
CHRM5 P08912 2/20 0.60
HTR2B P41595 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mepenzolate SCHEMBL17071946 0.97 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL44191 0.97 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL2994933 0.97 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL15575855 0.96 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL147471 0.96 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL15575981 0.96 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL17008166 0.96 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL99030 0.96 CHRM3 (1.00) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL3401786 0.95 CHRM3 (0.97) CHRM3CHRM2KCNH2CYP2D6LMNA
Mepenzolate SCHEMBL9441937 0.95 CHRM3 (0.97) CHRM3CHRM2KCNH2CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2148701-A2 IMAGING CONTRAST AGENTS USING NANOPARTICLES Carestream Health, Inc. (US) 2010-02-03 EP disclosed
WO-2008140475-A2 IMAGING CONTRAST AGENTS USING NANOPARTICLES CARESTREAM HEALTH, INC. (US) 2008-11-20 WO disclosed
US-20080095699-A1 IMAGING CONTRAST AGENTS USING NANOPARTICLES CARESTREAM HEALTH, INC. 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080095699-A1 IMAGING CONTRAST AGENTS USING NANOPARTICLES CD47, MSN, CLTA CHRM3 2073/4885CHRM1 1654/4885CHRM2 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.